Feasibility of low‑dose infusion of alteplase for unsuccessful thrombolysis with urokinase in deep venous thrombosis

Gong,Maofeng; Zhao,Boxiang; He,Xu; Gu,Jianping; Chen,Guoping

doi:10.3892/etm.2019.7938

Feasibility of low‑dose infusion of alteplase for unsuccessful thrombolysis with urokinase in deep venous thrombosis

Authors:
- Maofeng Gong
- Boxiang Zhao
- Xu He
- Jianping Gu
- Guoping Chen
View Affiliations

Affiliations: Department of Interventional Radiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu 210006, P.R. China
Published online on: August 26, 2019 https://doi.org/10.3892/etm.2019.7938
Pages: 3667-3674

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate whether the rescue of thrombolysis with the recombinant tissue plasminogen activator (rt‑PA) alteplase was an effective and safe therapeutic option in patients who did not respond to urokinase. Between February 2016 and February 2017, 26 patients with deep venous thrombosis (DVT) underwent rescue thrombolysis with alteplase. Unsuccessful thrombolysis with urokinase was defined as a lack of improvement in the degree of thrombotic removal with a lysis rate <50% under one of the following three conditions: Two consecutive venography procedures, administration of >3 million units of total urokinase, or >7 days infusion duration. The thrombus score, lysis rate and post‑thrombolysis safety of alteplase, following unsuccessful urokinase thrombolysis were all evaluated. At the end of the unsuccessful urokinase thrombolytic therapy, the mean duration of the perfusion was 6.09±1.60 days, and the mean total dose was (362.5±90.0) x104 units. No significant difference was detected in the total thrombus score before (7.85±2.40) and at the completion (6.19±2.33) of urokinase thrombolysis (P>0.05). The mean duration of perfusion was 3.36±1.69 days, and the mean total infusion dose was 44.8±22.6 mg for the rescue thrombolysis with alteplase. The mean thrombus score decreased to 1.19±2.10 at the completion of rescue thrombolysis. The alteplase post‑thrombolysis scores were significantly decreased compared with those of urokinase thrombolysis (P<0.05). There were 23 (88.5%) patients who achieved a successful lysis rate (grade II/III) following rescue thrombolysis with alteplase, and symptoms of swelling and pain in the affected limbs were significantly improved. Successful thrombolysis rates in patients in the acute (<14 days) and subacute (14‑28 days) phases were high (93.3 and 81.8%, respectively; P>0.05). No symptomatic pulmonary embolism or major bleeding occurred during rescue thrombolysis, but minor bleeding complications occurred in 4 cases (15.4%). In conclusion, rescue thrombolysis with alteplase led to an effective and safe outcome in patients with DVT who did not respond to initial thrombolysis with urokinase, and may be a valid and easy alternative treatment option.

View Figures

View References

1	Kearon C: Natural history of venous thromboembolism. Circulation. 107 (Suppl 1):S122–S130. 2003. View Article : Google Scholar
2	Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, Huisman M, King CS, Morris TA, Sood N, et al: Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 149:315–352. 2016. View Article : Google Scholar : PubMed/NCBI
3	Haig Y, Enden T, Grøtta O, Kløw NE, Slagsvold CE, Ghanima W, Sandvik L, Hafsahl G, Holme PA, Holmen LO, et al: Post-thrombotic syndrome after catheter-directed thrombolysis for deep vein thrombosis (CaVenT): 5-year follow-up results of an open-label, randomised controlled trial. Lancet Haematol. 3:64–71. 2016. View Article : Google Scholar
4	Watson L, Broderick C and Armon MP: Thrombolysis for acute deep vein thrombosis. Cochrane Database Syst Rev. Nov 10–2016.(Epub ahead of print). doi: 10.1002/14651858.CD002783.pub3. View Article : Google Scholar
5	Gurman P, Miranda OR, Nathan A, Washington C, Rosen Y and Elman NM: Recombinant tissue plasminogen activators (rtPA): A review. Clin Pharmacol Ther. 97:274–285. 2015. View Article : Google Scholar : PubMed/NCBI
6	Meneveau N, Seronde MF, Blonde MC, Legalery P, Didier-Petit K, Briand F, Caulfield F, Schiele F, Bernard Y and Bassand JP: Management of unsuccessful thrombolysis in acute massive pulmonary embolism. Chest. 129:1043–1050. 2006. View Article : Google Scholar : PubMed/NCBI
7	Vedantham S, Sista AK, Klein SJ, Nayak L, Razavi MK, Kalva SP, Saad WE, Dariushnia SR, Caplin DM, Chao CP, et al: Quality improvement guidelines for the treatment of lower-extremity deep vein thrombosis with use of endovascular thrombus removal. J Vasc Interv Radiol. 25:1317–1325. 2014. View Article : Google Scholar : PubMed/NCBI
8	Decousus H, Leizorovicz A, Parent F, Page Y, Tardy B, Girard P, Laporte S, Faivre R, Charbonnier B, Barral FG, et al: A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med. 338:409–415. 1998. View Article : Google Scholar : PubMed/NCBI
9	Chen G, Shi W, He X, Lou W, Chen L and Gu J: Feasibility of continuous, catheter-directed thrombolysis using low-dose urokinase in combination with low molecular-weight heparin for acute iliofemoral venous thrombosis in patients at risk of bleeding. Exp Ther Med. 13:751–758. 2017. View Article : Google Scholar : PubMed/NCBI
10	Shi WY, Gu JP, Liu CJ, He X and Lou WS: Endovascular treatment for iliac vein compression syndrome with or without lower extremity deep vein thrombosis: A retrospective study on mid-term in-stent patency from a single center. Eur J Radiol. 85:7–14. 2016. View Article : Google Scholar : PubMed/NCBI
11	Farraj RS: Anticoagulation period in idiopathic venous thromboembolism. How long is enough? Saudi Med J. 25:848–851. 2004.
12	Kahn SR, Shapiro S, Wells PS, Rodger MA, Kovacs MJ, Anderson DR, Tagalakis V, Houweling AH, Ducruet T, Holcroft C, et al: Compression stockings to prevent post-thrombotic syndrome: A randomised placebo-controlled trial. Lancet. 383:880–888. 2014. View Article : Google Scholar : PubMed/NCBI
13	Mewissen MW, Seabrook GR, Meissner MH, Cynamon J, Labropoulos N and Haughton SH: Catheter-directed thrombolysis for lower extremity deep venous thrombosis: Report of a national multicenter registry. Radiology. 211:39–49. 1999. View Article : Google Scholar : PubMed/NCBI
14	Haig Y, Enden T, Slagsvold CE, Sandvik L, Sandset PM and Kløw NE: Determinants of early and long-term efficacy of catheter-directed thrombolysis in proximal deep vein thrombosis. J Vasc Interv Radiol. 24:17–24. 2013. View Article : Google Scholar : PubMed/NCBI
15	Buller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob G, van den Berg-Segers AE, Cariou R, et al: Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med. 349:1695–1702. 2003. View Article : Google Scholar : PubMed/NCBI
16	Vedantham S, Piazza G, Sista AK and Goldenberg NA: Guidance for the use of thrombolytic therapy for thetreatment of venous thromboembolism. J Thromb Thrombolysis. 41:68–80. 2016. View Article : Google Scholar : PubMed/NCBI
17	Gao B, Zhang J, Wu X, Han Z, Zhou H, Dong D and Jin X: Catheter-directed thrombolysis with a continuous infusion of low-dose urokinase for non-acute deep venous thrombosis of the lower extremity. Korean J Radiol. 12:97–106. 2011. View Article : Google Scholar : PubMed/NCBI
18	Sugimoto K, Hofmann LV, Razavi MK, Kee ST, Sze DY, Dake MD and Semba CP: The safety, efficacy, and pharmacoeconomics of low-dose alteplase compared with urokinase for catheter-directed thrombolysis of arterial and venous occlusions. J Vasc Surg. 37:512–517. 2003. View Article : Google Scholar : PubMed/NCBI
19	Chang R, Chen CC, Kam A, Mao E, Shawker TH and Horne MK III: Deep vein thrombosis of lower extremity: Direct intraclot injection of alteplase once daily with systemic anticoagulation-results of pilot study. Radiology. 246:619–629. 2008. View Article : Google Scholar : PubMed/NCBI
20	Manninen H, Juutilainen A, Kaukanen E and Lehto S: Catheter-directed thrombolysis of proximal lower extremity deep vein thrombosis: A prospective trial with venographic and clinical follow-up. Eur J Radiol. 81:1197–1202. 2012. View Article : Google Scholar : PubMed/NCBI
21	Fiengo L, Bucci F, Khalil E and Salvati B: Original approach for thrombolytic therapy in patients with Ilio-femoral deep vein thrombosis: 2 years follow-up. Thromb J. 13:402015. View Article : Google Scholar : PubMed/NCBI